// App-Quantinova.ai

e15103 : Adoption rates of immune checkpoint inhibitors in real world oncology practice.

Researchers

Presenter

  • Jennifer O. Nwankwo

Principal Investigators

  • Charles Lagor

  • Hemant Tiwari

  • Robert Fair

  • Tom Brasington

  • Douglas Terrell

  • Jeffrey Kaufman

  • Faith DeFreitas

  • Brigham Hyde

  • Edward J. Stepanski

  • Mark S. Walker

Medical Centers

  • Precision Health Ai, New York, NY

  • ProMetrics LLC, King of Prussia, PA

  • ProMetrics LLC, King of Prussia, PA

  • Vector Oncology, Memphis, TN

Locations

  • United States

Companies

  • ProMetrics, LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Atezolizumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved